| Browse All

Autolus Therapeutics plc (AUTL)

Healthcare | Biotechnology | London, United Kingdom | NasdaqGS
1.57 USD -0.01 (-0.633%) ⇩ (April 21, 2026, 10:50 a.m. EDT)

Short-term: ★★★★☆ | Long-term: ★★★☆☆ | Dividends: ☆☆☆☆☆
Hot Take | April 18, 2026, 10:34 p.m. EDT

Autolus is positioned for a catalyst-driven run-up despite deteriorating short-term earnings. The options market is pricing in a move to $2.00+ within weeks, while the fundamental data supports a 'Strong Buy' long-term due to massive cash reserves (approx $217M) against a negligible market cap, yet the price action remains suppressed by recent revenue miss negativity. This creates a high-risk/high-reward asymmetric setup where the fundamental valuation (P/B 0.27) clashes with market sentiment, requiring a strong Q2 readout on autoimmune data to unlock value.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoTheta ✓0.068911
AutoARIMA0.072424
AutoETS0.072424
MSTL0.074295

Forecast horizon: 45 days | Selected: AutoTheta

Forecast Reliability
Score 80%
H-stat 0.78
Ljung-Box p 0.000
Jarque-Bera p 0.333
Excess Kurtosis -0.22
Attribute Value
Sector Healthcare
Revenue per Share 0.028
Market Cap 417,844,960
Forward P/E -2.21
Website https://www.autolus.com

As of April 18, 2026, 10:34 p.m. EDT: Options flow shows distinct bullish skew for the next month. April 17 OTM calls (Strike 2.0) have significantly higher OI and volume than puts at the same strike, with a dist_pct of +25.0%. Volatility is muted for calls (3-8%) but elevated for near-term puts (16.69%), suggesting tight bid-ask spreads or dealer inventory management rather than panic selling. Long-term options show massive volume in ITM/ATM calls over OTM for June expiration (416 vs 20 external vol), indicating speculation on a larger multi-month move to the upside rather than downside protection. The dominance of ATM options (dist_pct -6.3%) suggests hedging activity or liquidity provision, while the specific flow at 2.0 strikes for expiration levels points to price targets above current ~1.60.


Info Dump

Attribute Value
52 Week Change -0.012499988
Address1 The Mediaworks
Address2 191 Wood Lane White City
All Time High 53.24
All Time Low 1.105
Ask 1.97
Ask Size 2
Average Analyst Rating 1.1 - Strong Buy
Average Daily Volume10 Day 1,455,430
Average Daily Volume3 Month 1,639,724
Average Volume 1,639,724
Average Volume10Days 1,455,430
Bid 1.18
Bid Size 4
Book Value 5.91
City London
Compensation As Of Epoch Date 1,767,139,200
Country United Kingdom
Crypto Tradeable 0
Currency USD
Current Price 1.57
Current Ratio 11.054
Custom Price Alert Confidence HIGH
Date Short Interest 1,774,915,200
Day High 1.58
Day Low 1.52
Display Name Autolus Therapeutics
Earnings Call Timestamp End 1,774,614,600
Earnings Call Timestamp Start 1,774,614,600
Earnings Timestamp 1,774,614,600
Earnings Timestamp End 1,778,157,000
Earnings Timestamp Start 1,778,157,000
Ebitda -68,942,608
Ebitda Margins 0.0
Enterprise To Ebitda 2.252
Enterprise To Revenue -143.951
Enterprise Value -155,250,720
Eps Current Year -0.93375
Eps Forward -0.71179
Eps Trailing Twelve Months -1.08
Esg Populated 0
Exchange NMS
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 1.4995
Fifty Day Average Change 0.070500016
Fifty Day Average Change Percent 0.047015682
Fifty Two Week Change Percent -1.2499988
Fifty Two Week High 2.7
Fifty Two Week High Change -1.13
Fifty Two Week High Change Percent -0.4185185
Fifty Two Week Low 1.15
Fifty Two Week Low Change 0.42000008
Fifty Two Week Low Change Percent 0.36521748
Fifty Two Week Range 1.15 - 2.7
Financial Currency USD
First Trade Date Milliseconds 1,529,674,200,000
Float Shares 33,904,120
Forward Eps -0.71179
Forward P E -2.2057068
Full Exchange Name NasdaqGS
Full Time Employees 752
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Gross Profits -26,476,000
Has Pre Post Market Data 1
Held Percent Insiders 0.18083
Held Percent Institutions 0.77596
Implied Shares Outstanding 266,143,287
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Long Business Summary Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Long Name Autolus Therapeutics plc
Market us_market
Market Cap 417,844,960
Market State REGULAR
Max Age 86,400
Message Board Id finmb_562879769
Most Recent Quarter 1,546,214,400
Net Income To Common -53,279,500
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 423,167,824
Number Of Analyst Opinions 10
Open 1.58
Operating Margins -65.70746
Payout Ratio 0.0
Phone 44 20 3829 6230
Previous Close 1.58
Price Eps Current Year -1.6813923
Price Hint 4
Price To Book 0.26565146
Price To Sales Trailing12 Months 387.43158
Profit Margins 0.0
Quick Ratio 10.317
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key strong_buy
Recommendation Mean 1.09091
Region US
Regular Market Change -0.00999999
Regular Market Change Percent -0.6329108
Regular Market Day High 1.58
Regular Market Day Low 1.52
Regular Market Day Range 1.52 - 1.58
Regular Market Open 1.58
Regular Market Previous Close 1.58
Regular Market Price 1.57
Regular Market Time 1,776,783,011
Regular Market Volume 392,537
Return On Assets -0.22275
Return On Equity -0.29621
Revenue Per Share 0.028
Sand P52 Week Change 0.34445214
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 266,143,286
Shares Percent Shares Out 0.0548
Shares Short 14,582,459
Shares Short Previous Month Date 1,772,150,400
Shares Short Prior Month 14,966,126
Short Name Autolus Therapeutics plc
Short Percent Of Float 0.0845
Short Ratio 8.04
Source Interval 15
Symbol AUTL
Target High Price 13.0
Target Low Price 5.0
Target Mean Price 8.81
Target Median Price 9.0
Total Cash 217,450,000
Total Cash Per Share 5.524
Total Debt 0
Total Revenue 1,078,500
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -1.08
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 1.652975
Two Hundred Day Average Change -0.08297491
Two Hundred Day Average Change Percent -0.05019732
Type Disp Equity
Volume 392,537
Website https://www.autolus.com
Zip W12 7FP